Physician profile
Michele Winchell
NPI 1447568290
$4,809.47
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $986 · 2023: $2,350 · 2024: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,478 · Education: $96.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,477.67 |
| Education | $96.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,516.85 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $462.09 | 2022-2024 | Austedo Xr, Austedo, Ajovy |
| Ucb, INC. | $257.63 | 2023-2024 | Briviact, Fintepla |
| Catalyst Pharmaceuticals, INC. | $253.12 | 2023-2024 | Fycompa |
| Eisai INC. | $221.67 | 2023-2024 | |
| Pfizer INC. | $213.73 | 2023-2024 | |
| Neurelis, INC. | $201.13 | 2023-2024 | Valtoco |
| Sk Life Science, INC. | $191.87 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $164.57 | 2023-2024 | Aptiom |
| Jazz Pharmaceuticals INC. | $153.97 | 2023-2024 | |
| Lundbeck LLC | $113.20 | 2023-2024 | Vyepti |
| Lilly USA, LLC | $110.74 | 2021-2024 | Emgality, Reyvow |
| Corium, LLC | $87.76 | 2022-2023 | Azstarys |
| Alexion Pharmaceuticals, INC. | $84.69 | 2022 | |
| Livanova USA, INC. | $65.43 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Winchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.